About 3 500 reports

Ltd Savient Pharmaceuticals Shandong Kexing Pharma Shanghai Celgen Biopharmaceuticals Shanghai CP Guojian Shanghai Fosun Pharmaceutical Shanghai Henlius Biotech Shanghai Lansheng Guojian Pharmaceutical Co.

  • Biopharmaceutical
  • Biosimilar
  • Pharmaceutical
  • China
  • Company
  • provides a SWOT analysis of Roche.
  • ROCHE SWOT ANALYSIS, 2017

OBI Pharma (2016).

  • Pharmaceutical
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • PRODUCT PROFILE - QUADRIVALENT SEASONAL INFLUENZA VLP VACCINE
  • 9.2 TRENDS IN CORPORATE STRATEGY

MITSUBISHI TANABE PHARMA (2016).

  • Pharmaceutical
  • Europe
  • Company
  • CSL Limited
  • Daiichi Sankyo Company
  • CHF-5993 (BECLOMETHASONE DIPROPIONATE + FORMOTEROL FUMARATE + GLYCOPYRROLATE)
  • COMPANY PORTFOLIO GAP ANALYSIS IN COPD, 2015-2025

IN OCTOBER 2009, SEPRACOR WAS ACQUIRED BY DAINIPPON SUMITOMO PHARMA, AN OSAKA, JAPAN-BASED PHARMACEUTICAL COMPANY.

  • Pharmaceutical
  • Company
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • 7.1 GALENICA GROUP
  • Galenica's Net Sales Share by Region (2016)

Vifor Pharma is an international specialty pharma company that researches, develops, produces and markets its own pharmaceutical products.

  • Pharmaceutical
  • Company
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Galenica Group
  • Current and Future Players
  • KEY COMPANIES IN THE SLE AND LN MARKET IN THE 7MM, 2016

ANTHERA PHARMACEUTICALS (2015).

  • Pharmaceutical
  • World
  • Company
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • NAPABUCASIN'S CLINICAL DEVELOPMENT IN CRC
  • TECENTRIQ'S CLINICAL DEVELOPMENT IN CRC

TAIHO PHARMACEUTICALS (2016).

  • Pharmaceutical
  • Company
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • GLOBAL SALES FORECAST ($M) FOR GUSELKUMAB, 2014-2024
  • PRESENTS THE GLOBAL SALES FORECAST FOR GUSELKUMAB DURING 2014-2024.

LEO PHARMA (2015).

  • Pharmaceutical
  • World
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • POST-HSCT EFFICACY ANALYSIS OF THE PHASE III TRIAL (CELATOR, NCT01696084) OF VYXEOS IN
  • EFFICACY OF VYXEOS VERSUS 7+3 IN THE PHASE III TRIAL (CELATOR, NCT01696084)

MEI PHARMA (2016).

  • Pharmaceutical
  • Company
  • Astellas Pharma Inc.
  • Celgene Corporation
  • Novartis AG
  • 4.3 ANTARES PHARMA INC
  • 4.2.1 Company Overview
  • Pharmaceutical
  • France
  • Company
  • Antares Pharma, Inc.
  • Bioject Medical Technologies Inc.
  • 4.3 ANTARES PHARMA INC
  • 4.2.1 Company Overview
  • Pharmaceutical
  • Italy
  • Company
  • Antares Pharma, Inc.
  • Bioject Medical Technologies Inc.
  • 2.2 BIG PHARMA FOCUSES ON LABEL EXPANSION, WHILE SMALLER COMPANIES FOCUS ON DEVELOPING DRUGS WITH NOVEL MECHANISMS OF ACTION
  • 8.2 PROMISING DRUGS IN CLINICAL DEVELOPMENT
  • Pharmaceutical
  • Japan
  • Company
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • 6.3 Orion Corporation
  • ORION CORPORATION NET SALES BY SEGMENTS; 2016

On February ##, 2016 Swiss pharmaceutical company Primex Pharmaceuticals AG and French pharmaceutical laboratory Advicenne SA announced that Primex acquired global rights for an advanced oral pharmaceutical candidate for pediatric anesthesiology developed by Advic

  • Pharmaceutical
  • Europe
  • Company
  • Demand
  • Aspen Pharmacare Holdings Limited
  • Acquisitions of Valeant Pharmaceuticals
  • 6. Company Profiling
  • Pharmaceutical
  • United States
  • Company
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • OTHER DRUGS IN PHASE II OF CLINICAL DEVELOPMENT FOR HIV, 2016
  • VIIV'S DOLUTEGRAVIR/LAMIVUDINE - PHASE III CLINICAL TRIALS

TITUSVILLE, NEW JERSEY, US: JANSSEN PHARMACEUTICALS; 2016.

  • Pharmaceutical
  • Asia
  • Japan
  • Company
  • Gilead Sciences, Inc.
  • NOVARTIS' NSCLC PORTFOLIO ASSESSMENT, 2016
  • BMS SWOT ANALYSIS IN NSCLC, 2016

ASTELLAS PHARMA (2016).

  • Pharmaceutical
  • Company
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.
  • OTHER PRODUCTS IN CLINICAL DEVELOPMENT FOR HCV INFECTION, 2016
  • CLINICAL DEVELOPMENT OUTSIDE 9MM, 2016

TOKYO, JAPAN: CHUGAI PHARMACEUTICAL.

  • Pharmaceutical
  • Company
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • SUMMARY OF AES FROM THE PHASE II TRIAL OF NIMOTUZUMAB IN COMBINATION WITH IRINOTECAN
  • SUMMARY OF RESULTS FROM A PHASE II TRIAL OF ABRAXANE

PHARMA JAPAN WEB.

  • Pharmaceutical
  • Company
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • AVELUMAB'S DEVELOPMENT IN RCC
  • AVEO ONCOLOGY'S RCC PORTFOLIO ASSESSMENT, 2016

PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA) (2014).

  • Pharmaceutical
  • Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.
  • TETRAPHASE PHARMACEUTICALS INC. N/A
  • COMPANY PORTFOLIO GAP ANALYSIS FOR HAIS AGAINST GRAM-NEGATIVE BACTERIA, 2016-2026
  • Anti-Infective
  • Hospital
  • Pharmaceutical
  • Therapy
  • Company
  • Galmed Pharmaceuticals
  • NASH Development Pipeline of Galmed Pharmaceuticals
  • Pharmaceutical
  • World
  • Company
  • Galectin Therapeutics Inc.
  • Galmed Pharmaceuticals Ltd.
  • AGENTS IN PHASE I OR EARLY PHASE II CLINICAL DEVELOPMENT FOR CHRONIC HEPATITIS B
  • OTHER AGENTS IN CLINICAL DEVELOPMENT FOR CHRONIC HEPATITIS B TREATMENT, 2015

TETRALOGIC PHARMACEUTICALS (2015).

  • Pharmaceutical
  • Company
  • Gilead Sciences, Inc.
  • Novartis AG
  • Roche Group
  • 6.3 COMPANY PROFILES
  • 6.2 TRENDS IN CORPORATE STRATEGY

IN THE MOST COMMON MODEL, A PHARMACEUTICAL COMPANY FORMS A PARTNERSHIP WITH A DIAGNOSTIC TEST COMPANY.

  • Pharmaceutical
  • Company
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • bioMerieux S.A.
  • Product Profile - Remicade
  • presents the global sales forecast for tildrakizumab during 2014-2024.

LEO Pharma (2015).

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Product Profile - Remicade
  • presents the global sales forecasts for Otezla during 2014-2024.

LEO Pharma (2015).

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Product Profile - Remicade
  • Global Sales Forecast ($m) for Otezla, 2014-2024

LEO Pharma (2015).

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Product Profile - Remicade
  • presents the global sales forecast for tildrakizumab during 2014-2024.

LEO Pharma (2015).

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

The agreement allows TT-## to be co-marketed by Teijin Pharma Limited, the core company of the Teijin Group' s medical and pharmaceutical business, and Taisho Toyama Pharmaceutical Co., Ltd. of the Taisho Pharmaceutical Group.

  • Pharmaceutical
  • Asia
  • China
  • Company
  • Bayer AG
  • 8.1.3 MERCK & CO ENTERS INTO AGREEMENT WITH ARIAD PHARMA
  • PROSTATE CANCER THERAPEUTICS, GLOBAL, LICENSING DEALS BY MECHANISM OF ACTION,
  • Pharmaceutical
  • World
  • Company
  • Novartis AG
  • PROVENGE group
  • FERRING PHARMACEUTICALS
  • PROGENICS PHARMACEUTICALS: ADC PIPELINE
  • Pharmaceutical
  • United States
  • Company
  • AbbVie Inc.
  • Seattle Genetics, Inc.